After a phenomenal run in 2025, we aren’t slowing down. Our goal is to bring that same winning energy and precise execution into 2026. To make sure you’re getting the most out of our research, we’ve launched additional platforms so you can get firsthand access to everything we’re doing. You can even head over to the iOS App Store and download ChartSwipe or subscribe to our Powerhouse newsletters visit powerhouse.substack.com to get direct access to our email updates and community.
We’ve been busy scanning the markets, looking for high-growth stocks with massive AI catalysts that aren’t trading at “nosebleed” valuations. We want strong P/E ratios and clear fundamental runways. Here are the stocks on our radar for the week.
1. Micron Technology (MU)
Micron is a powerhouse in the memory and storage space, and it’s a core play for our “growth at a reasonable price” strategy. Our research led us to MU because it sits at the intersection of high-bandwidth memory (HBM) and the massive infrastructure build-out for artificial intelligence.
- The Catalyst: Micron recently reported a massive earnings beat, with revenue jumping nearly 20% over expectations due to explosive DRAM demand from cloud data centers.
- The Valuation: Despite the stock being up roughly 70% year-to-date, it maintains a solid P/E ratio (currently around 24x), making it much more attractive than other overextended AI plays.
- Technical Play: We are watching MU closely this week for a potential breakout or a healthy retest of the $528level. With analyst price targets now stretching toward $700, this is a “must-watch” for anyone trading the AI supercycle.
2. Cardiol Therapeutics (CRDL)
This one is for the researchers looking for a high-upside “smart money” play. CRDL has seen significant growth on the charts recently, but the real story is in the ownership.
$CRDL FEATURED IN THE WALLSTVAULT.COM
- Follow the Money: According to Whale Wisdom, a major fund has been accumulating a massive position. Anytime you see “Smart Money” loading up on a stock trading under $2, you have to pay attention.
- The Newsroom: The company has been incredibly active, expanding its MAVERIC Phase III clinical trials and maintaining a steady flow of solid news.
3. Advanced Micro Devices (AMD)
If you’re looking for a stock with a massive immediate catalyst, look no further than AMD. We are going deep on this one because the next few days could be pivotal.
The Setup: AMD has been on a tear, recently hitting all-time highs near $360. While the stock saw a 17% dip earlier in the year due to revenue sustainability questions, it has completely reclaimed its momentum.
Why We Like It Right Now:
- The Earnings Catalyst: AMD is set to report earnings on May 5. The market is expecting revenue growth of around 33% year-over-year (roughly $9.87B).
- The “Intel Read-Through”: We saw Intel post strong Data Center and AI revenue growth recently. This acts as a major precursor, suggesting that AMD—which has been eating Intel’s market share—could be in for a “blowout” surprise.
- Big Tech Partnerships: Meta recently agreed to a deal worth up to $60 billion for AMD chips. This provides a massive fundamental floor for the stock’s growth through 2026.
- Price Targets: Top-tier analysts at DA Davidson and CFRA have recently hiked their price targets to $375 and $400, respectively.
The Trade: Watch for AMD to hold the $350 support level heading into the May 5th announcement. If they provide strong guidance on their Helios GPU ramp-up for the second half of 2026, we could see a massive “blue sky” breakout.
Becoming a consistent trader is not easy.
Most fail.
At News On Wall Street we have a program.
Nothing is guaranteed but, we are opening the doors!
Text us at 844-722-9743.
LEGAL COMPLIANCE & DISCLOSURES
NOT FINANCIAL ADVICE – EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY All information provided by News On Wall Street (the “Publisher”) is strictly for educational and informational purposes only. Nothing contained herein constitutes, or is intended to constitute, investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. The Publisher is not a registered investment adviser, broker-dealer, or financial planner with any regulatory agency. We do not provide personalized investment recommendations and have no fiduciary duty to any reader or subscriber.
You should consult with a qualified, licensed financial professional (such as a registered investment adviser or broker-dealer) who can assess your individual financial situation, risk tolerance, investment objectives, and tax consequences before making any investment decision. Investing in micro-cap biotechnology stocks like Cardiol Therapeutics ($CRDL) carries extreme risk, including the potential for total loss of principal. Biotech companies frequently experience total failure of clinical programs, regulatory rejection, massive dilution, delisting, or bankruptcy. Volatility can be extreme, with shares sometimes moving 50% or more in a single day on news events.
HIGH-RISK WARNING SPECIFIC TO BIOTECHNOLOGY INVESTING Biotechnology investing is inherently binary and speculative. Most clinical-stage companies never generate profits, never receive regulatory approval, and ultimately result in significant or total investor losses. Factors that could cause actual results to differ materially from any expectations expressed here include (but are not limited to): failure of Phase II or Phase III clinical trials (such as the ARCHER or MAVERIC trials referenced), delays or denial of FDA or other regulatory approvals, manufacturing issues, competition from larger pharmaceutical companies, intellectual property challenges, dilution from future financings, changes in healthcare policy, clinical safety concerns, adverse events, inability to secure additional funding, loss of key personnel, and general market or economic conditions. Past clinical data is not a guarantee of future success in larger trials or commercialization.
FORWARD-LOOKING STATEMENTS SAFE HARBOR This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “project,” “may,” “will,” “could,” “should,” “potential,” “intend,” “forecast,” “target,” or similar expressions.
All forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve risks and uncertainties. These statements speak only as of the date they are made, and the Publisher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those expressed or implied due to the numerous risks outlined above and in Cardiol’s SEC filings (10-K, 10-Q, 8-K, etc.). Nothing in this report is a guarantee of future performance, clinical success, regulatory approval, commercialization, or stock price appreciation.
SEC RULE 17(b) DISCLOSURE (PAID PROMOTION / AWARENESS CAMPAIGN) News On Wall Street (the “Publisher”) has been compensated $100,000 in cash by Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) for the creation, distribution, and ongoing awareness efforts related to this report and associated content. This compensation covers the period from April 7, 2026, through May 27, 2026. The payment was made directly by the Company (or its agents) to the Publisher and constitutes a material conflict of interest.
This entire communication is a paid advertisement / sponsored awareness campaign. The Publisher was compensated specifically to publish, publicize, and circulate information regarding Cardiol’s securities. Under Section 17(b) of the Securities Act of 1933, this disclosure is required. Investors must assume that the Publisher’s objectivity is influenced by this relationship. THIS IS NOT INDEPENDENT RESEARCH. It is commissioned, paid-for promotional material. The Publisher is not acting as an independent analyst and does not claim to provide unbiased or impartial analysis.
CONFLICT OF INTEREST DISCLOSURE The Publisher and/or its principals, affiliates, officers, directors, employees, family members, or other associated parties may currently hold, or may in the future purchase or sell, positions in Cardiol Therapeutics ($CRDL) or any other securities mentioned without prior or subsequent notice to readers. The Publisher may buy or sell shares at any time, including before, during, or after the distribution of this report. This creates an inherent conflict of interest.
INFORMATION SOURCES, ACCURACY, AND LIABILITY Information in this report is derived from public sources believed to be reliable (Company press releases, SEC filings, etc.). However, the Publisher makes no representation or warranty as to the accuracy, completeness, or timeliness of any information provided. To the fullest extent permitted by law, News On Wall Street, its officers, directors, and affiliates shall not be liable for any direct, indirect, or consequential damages arising out of the use of this report, including trading losses or loss of profits.
PERFORM YOUR OWN DUE DILIGENCE (DYOR) Always conduct your own thorough independent research. Review Cardiol’s latest SEC filings at www.sec.gov, consult multiple independent sources, and speak with your own financial and legal advisors before investing. Do not rely solely on any paid promotional material.
By continuing to read or act upon any information provided by News On Wall Street, you acknowledge that you have read, understood, and agreed to this full Legal Compliance & Disclosures section in its entirety.
